| Ytd | 51.61% | |
| 1y | 10.03% |
| Open | 3.28 | Prev Close | 3.30 | Low | 3.11 | High | 3.29 | Mkt Cap | 7.54M |
| Vol | 11.34K | Avg Vol | 33.46K | EPS | -1.20 | P/E | -2.74 | Forward P/E | -6.20 |
| Beta | 2.26 | Short Ratio | 0.77 | Inst. Own | 2.10% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 2.90 | 200-d Avg | 2.73 | 1yr Est | 4.00 |
XBIO News
Expanded collaborative research initiatives reinforce the Company's long-term DNase development stra
Company evaluating systemic recombinant human DNase I in combination with anti-CD19 CAR T cells targ
New preclinical and translational findings position DNase I as a potentially transformative adjunct
Advancements across investigator-initiated studies, translational research and manufacturing activit
FRAMINGHAM, MA / ACCESS Newswire / April 22, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xeneti
Klotho Neurosciences (NASDAQ: KLTO - Get Free Report) and Xenetic Biosciences (NASDAQ: XBIO - Get Fr
Encouraging preclinical and translational data supporting DNase-based approaches to target NETs in d
Xenetic Biosciences (NASDAQ: XBIO - Get Free Report) and Ainos (NASDAQ: AIMD - Get Free Report) are
Xenetic Biosciences, Inc. (NASDAQ: XBIO - Get Free Report) was the recipient of a large growth in sh
Cumberland Pharmaceuticals (NASDAQ: CPIX - Get Free Report) and Xenetic Biosciences (NASDAQ: XBIO -
Crinetics Pharmaceuticals (NASDAQ: CRNX - Get Free Report) and Xenetic Biosciences (NASDAQ: XBIO - G
Xenetic Biosciences, Inc. (NASDAQ: XBIO - Get Free Report) was the recipient of a significant declin
Adjourns 2025 Annual Meeting of Stockholders Urges Stockholders Who Have Not Voted To Get Votes In F
FRAMINGHAM, MA / ACCESS Newswire / November 19, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xen
Continued execution on collaborations and exploratory investigator-initiated studies with institutio
FRAMINGHAM, MA / ACCESS Newswire / October 10, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xene
Expanded strategic partnership with The Scripps Research Institute to advance proof-of-concept studi
Xenetic Biosciences (XBIO) came out with a quarterly loss of $0.45 per share versus the Zacks Consen
Investigator initiated study with collaboration partner, PeriNess, to be conducted at the Tel-Aviv S
Research and development collaboration program to include additional models of lymphoma and leukemia
During Friday's trading, 293 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Thursday
40 Stocks Moving In Tuesday's Mid-Day Session
26 Stocks Moving In Tuesday's Pre-Market Session
44 Biggest Movers From Yesterday